Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMI1 | P35226 | 13/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16739823 | 1.00 | BMI1 (0.52) | BMI1KCNH2SCN5ASCN9ATDP1 | |
| SCHEMBL16748000 | 1.00 | BMI1 (0.52) | BMI1KCNH2SCN5ASCN9ATDP1 | |
| SCHEMBL16739664 | 0.92 | BMI1 (0.54) | BMI1KCNH2SCN5ASCN9AALOX5AP | |
| SCHEMBL16748010 | 0.90 | BMI1 (0.53) | BMI1KCNH2SCN5ASCN9ATDP1 | |
| SCHEMBL16739817 | 0.86 | BMI1 (0.47) | BMI1KCNH2SCN5ASCN9AKMT2A | |
| SCHEMBL16747819 | 0.86 | BMI1 (0.47) | BMI1KCNH2SCN5ASCN9AKMT2A | |
| SCHEMBL18103432 | 0.86 | TDP1 (0.39) | BMI1TDP1TP53KMT2AMEN1 | |
| SCHEMBL16740311 | 0.84 | BMI1 (0.54) | BMI1KCNH2SCN5ASCN9ATDP1 | |
| SCHEMBL16739912 | 0.84 | BMI1 (0.69) | BMI1KCNH2SCN5ASCN9A | |
| SCHEMBL16747895 | 0.83 | BMI1 (0.55) | BMI1KCNH2SCN5ASCN9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| WO-2015076800-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | BMI1, BAZ2A, BAZ2B | BMI1 1/4885KCNH2 3952/4885SCN5A 3115/4885 |
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | BMI1, BAZ2A, BAZ2B | BMI1 1/4885KCNH2 3952/4885SCN5A 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.